Global Osteoarthritis Pain Drugs Market Insights, Forecast to 2025
The main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis, osteoarthritis in the use of two kinds of painkillers:
Painkillers only: Only a simple analgesic effect, but no anti-inflammatory function, such as acetaminophen, tramadol. Acetaminophen side effects, but the analgesic effect is relatively weak, mainly for mild to moderate pain; tramadol analgesic effect is strong, but also side effects are larger, mainly gastrointestinal side effects such as nausea, vomiting and so on.
NSAIDs: With both anti-inflammatory and analgesic effect, suitable for inflammatory pain, for the acute phase of osteoarthritis, joint swelling of the patients to relieve symptoms better. These drugs may lead to nausea, vomiting and other gastrointestinal discomfort, but also increase the risk of gastrointestinal bleeding, so patients with gastro duodenal ulcer in the application of these drugs should consult a digestive physician, plus gastric mucosal protection Drugs or antacid drugs.
Medicines for Osteoarthritis Pain are available as pills, syrups, creams or lotions, or they are injected into a joint.
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement.
The USA osteoarthritis pain drugs market is very concerted market; the revenue of eleven manufacturers accounts about 88% of the total revenue in 2016. The high-end products mainly come from USA and Europe.
The leading manufactures mainly are Johnson & Johnson, Pfizer and GlaxoSmithKline. Johnson & Johnson is the largest manufacturer; its revenue of USA market exceeds 27% in 2016. The next is Pfizer and GlaxoSmithKline.
The global Osteoarthritis Pain Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Osteoarthritis Pain Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Osteoarthritis Pain Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Osteoarthritis Pain Drugs in these regions.
This research report categorizes the global Osteoarthritis Pain Drugs market by top players/brands, region, type and end user. This report also studies the global Osteoarthritis Pain Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Johnson & Johnson
Pfizer
GlaxoSmithKline
Mylan
Lilly
Sanofi
Abbott Laboratories
Bayer
Almatica Pharma
TEVA
Iroko Pharmaceuticals
Market size by Product
Oral
Injection
External
Market size by End User
Medical Care
Personal Care
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Osteoarthritis Pain Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Osteoarthritis Pain Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Osteoarthritis Pain Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Osteoarthritis Pain Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Osteoarthritis Pain Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (M Dose). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Osteoarthritis Pain Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Painkillers only: Only a simple analgesic effect, but no anti-inflammatory function, such as acetaminophen, tramadol. Acetaminophen side effects, but the analgesic effect is relatively weak, mainly for mild to moderate pain; tramadol analgesic effect is strong, but also side effects are larger, mainly gastrointestinal side effects such as nausea, vomiting and so on.
NSAIDs: With both anti-inflammatory and analgesic effect, suitable for inflammatory pain, for the acute phase of osteoarthritis, joint swelling of the patients to relieve symptoms better. These drugs may lead to nausea, vomiting and other gastrointestinal discomfort, but also increase the risk of gastrointestinal bleeding, so patients with gastro duodenal ulcer in the application of these drugs should consult a digestive physician, plus gastric mucosal protection Drugs or antacid drugs.
Medicines for Osteoarthritis Pain are available as pills, syrups, creams or lotions, or they are injected into a joint.
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement.
The USA osteoarthritis pain drugs market is very concerted market; the revenue of eleven manufacturers accounts about 88% of the total revenue in 2016. The high-end products mainly come from USA and Europe.
The leading manufactures mainly are Johnson & Johnson, Pfizer and GlaxoSmithKline. Johnson & Johnson is the largest manufacturer; its revenue of USA market exceeds 27% in 2016. The next is Pfizer and GlaxoSmithKline.
The global Osteoarthritis Pain Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Osteoarthritis Pain Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Osteoarthritis Pain Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Osteoarthritis Pain Drugs in these regions.
This research report categorizes the global Osteoarthritis Pain Drugs market by top players/brands, region, type and end user. This report also studies the global Osteoarthritis Pain Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Johnson & Johnson
Pfizer
GlaxoSmithKline
Mylan
Lilly
Sanofi
Abbott Laboratories
Bayer
Almatica Pharma
TEVA
Iroko Pharmaceuticals
Market size by Product
Oral
Injection
External
Market size by End User
Medical Care
Personal Care
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Osteoarthritis Pain Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Osteoarthritis Pain Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Osteoarthritis Pain Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Osteoarthritis Pain Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Osteoarthritis Pain Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (M Dose). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Osteoarthritis Pain Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
